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Abstract
Background: Health disparities and the high prevalence of cardiovascular disease continue to be perplexing
worldwide health challenges. This study addresses the possibility that genetic differences affecting the biology of
the vascular endothelium could be a factor contributing to the increased burden of cardiovascular disease and
cancer among African Americans (AA) compared to Caucasian Americans (CA).
Methods: From self-identified, healthy, 20 to 29-year-old AA (n = 21) and CA (n = 17), we established cultures of
blood outgrowth endothelial cells (BOEC) and applied microarray profiling. BOEC have never been exposed to in
vivo influences, and their gene expression reflects culture conditions (meticulously controlled) and donor genetics.
Significance Analysis of Microarray identified differential expression of single genes. Gene Set Enrichment Analysis
examined expression of pre-determined gene sets that survey nine biological systems relevant to endothelial
biology.
Results: At the highly stringent threshold of False Discovery Rate (FDR) = 0, 31 single genes were differentially
expressed in AA. PSPH exhibited the greatest fold-change (AA > CA), but this was entirely accounted for by a
homolog (PSPHL) hidden within the PSPH probe set. Among other significantly different genes were: for AA > CA,
SOS1, AMFR, FGFR3; and for AA < CA, ARVCF, BIN3, EIF4B. Many more (221 transcripts for 204 genes) were
differentially expressed at the less stringent threshold of FDR <.05. Using the biological systems approach, we
identified shear response biology as being significantly different for AA versus CA, showing an apparent tonic
increase of expression (AA > CA) for 46/157 genes within that system.
Conclusions: Many of the genes implicated here have substantial roles in endothelial biology. Shear stress
response, a critical regulator of endothelial function and vascular homeostasis, may be different between AA and
CA. These results potentially have direct implications for the role of endothelial cells in vascular disease
(hypertension, stroke) and cancer (via angiogenesis). Also, they are consistent with our over-arching hypothesis that
genetic influences stemming from ancestral continent-of-origin could impact upon endothelial cell biology and
thereby contribute to disparity of vascular-related disease burden among AA. The method used here could be
productively employed to bridge the gap between information from structural genomics (for example, disease
association) and cell function and pathophysiology.
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Despite the enormous advances over the last century in
the understanding of, and the ability to therapeutically
manipulate, medical biology, both health disparities and
the high prevalence of cardiovascular (including cerebro-
vascular) disease continue to be perplexing, worldwide
medical challenges. From a world health perspective, [1]
health disparities are evident comparing continents,
countries, regions, and population subgroups defined, for
example, by socioeconomic factors or ethnic/racial
group. The reasons these exist are legion, but they basi-
cally fall into the categories of environment (in the
broadest sense) and genetics. So understanding the basis
for extant health disparities is (or will be) a goal of health
delivery efforts worldwide.
The present study addresses a specific case of health
disparity that is particularly amenable to analysis, the
higher burden of cardiovascular disease borne by those of
African ancestry who reside within the United States. In
so doing, we illustrate the feasibility of a novel investiga-
tional approach that offers a way to bridge the current
gap between the information provided by structural
genomics (for example, identification of loci, genes,
alleles, haplotypes associated with disease or disease risk)
and the actual consequent impact upon cellular biology
and disease pathophysiology. Thus, by demonstrating
a way to link these two distinct facets of modern medial
biology for vascular disease, the present approach may be
very useful. For example, it could help tease out the enor-
mously confounding effect of inter-individual epigenetic
changes on attempts to associate a locus with a disease
phenotype.
Health disparity
Worldwide, coronary and cerebrovascular disease
account for approximately 20% of deaths, an estimated
7.2 and 5.7 million people annually, and they are the
two most common causes of death in high- and middle-
income countries [1]. This proportion rises to approxi-
mately 30% if all cardiovascular disease types (for exam-
ple, hypertension) are included. Even in low-income
countries, cardiovascular disease is exceeded as the
cause of death only by infectious diseases (in particular
malaria, diarrheal diseases, tuberculosis and HIV) [1].
Within the United States there are significant health
disparities between African Americans (AA) and Cauca-
sian Americans (CA). Notably, AA have a 2.4-fold higher
incidence of stroke [2] and an approximately 50%
increase in prevalence of hypertension, the latter affecting
approximately 31% of AA [3,4]. This same disparity exists
in the United Kingdom [5], and a local study verifies that
it occurs in our own region from which the present study
subjects were drawn [6]. In addition, AA display an
increased prevalence of cardiovascular co-morbidities
that contribute to pathogenesis in the general population
[7]. For example, obesity has a 50% higher prevalence
and affects approximately 45% of AA [8]. Correspond-
ingly, AA have a two- to three-fold higher prevalence of
type-2 diabetes so that it affects approximately 12% of
AA [9], and they have an increased incidence of smoking,
physical inactivity, and peripheral artery disease [10]. In
addition to bearing the burden of a higher prevalence of
cardiovascular and cerebrovascular disease, AA tend to
develop such clinical diseases at a younger age than do
CA (see Discussion). Disparities in cancer are addressed
in the Discussion.
The debate as to what relative degree environment
versus genetics causes these disparities is ongoing and
vigorous.
Environmental influences
The many factors interposed between racial identification
(see Discussion) and any health issue provide a perplex-
ing spectrum of possible non-genetic routes to disease
disparity [11]. Examples include nutrition and exposures,
access to health care and disparities in its delivery, social
conditions and lifestyle choices, and so on. For cardiovas-
cular health, it is telling that urbanization and its accom-
panying adoption of Western lifestyles are implicated in
the accelerating development of hypertension and its
comorbidities within Africa [12]. Likewise, the African
diaspora established parallel gradients of hypertension
and comorbid risk factors from West Africa to the Carib-
bean to North America [13,14]. Even within the United
States itself there are notable regional differences in
stroke mortality rate among AA [15]. Thus, the tremen-
dous influence of environmental factors is indisputable.
Genetic influences
The present study, however, was conducted considering
the possibility that the exaggerated burden among AA
of cardiovascular disease, and perhaps even that of
cancer, could stem in part from genetic determinants.
Indeed, historical genetic studies indicated that ancestral
continent-of-origin can be genetically identified [16].
Application of modern methods (for example, identi-
fication of single nucleotide polymorphisms [SNPs],
haplotypes, copy-number variable loci, genetic diversity,
frequency of non-beneficial SNPs) confirm an East
African origin for modern humans with the spread of the
human genome to the rest of the world [17-19]. In turn,
modern populations can carry genes that confer altered
risk (higher or lower) for disease burden [20]. Indeed,
newer methods such as discovery of disease association
through admixture mapping have implicated specific loci
influencing, for example, hypertension [21,22], blood
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studies of AA versus CA have been extremely helpful in
identifying the relationship between such loci and conti-
nent-of-origin.
Gene-environment interactions
Environmental and genetic influences do not occur
independently; rather, gene-environment interactions
contribute to disease variation [25]. Dramatic examples
of this in Africa include the sickle mutation, the Duffy
mutation, and APOL1 variants conferring protection
against P. falciparum,a n dP. vivax,a n dTrypanosoma
disease, respectively. On the other hand, gene variants
that are hypothesized to have been of benefit in ances-
tral Africa can exert a harmful effect in modern socie-
ties. For example, a CYP3A5 allele which may have been
advantageous in hot ancestral regions is now associated
with salt-sensitivity hypertension in modern AA [26].
Another example is, in principle, found in the “thrifty
gene” theory which posits that maximized calorie sto-
rage was advantageous ancestrally, but under modern
conditions of more abundant food availability, obesity
and type-2 diabetes (insulin resistance) are epidemic
problems [9].
Thus, obesity is substantially influenced by genetics and
is now understood to be a polygenic, complex disease
with very significant gene-environment interaction [27].
Likewise, the relevance of gene-environment interactions
has been emphasized for hypertension [28], stroke [29],
cardiovascular disease [30], as well as metabolic syn-
drome, diabetes and atherosclerosis [31]. Furthermore,
sequence-independent examples of this have been pro-
posed whereby environmental influences exerted during
development, for example, by poor prenatal nutrition,
could establish durable, even trans-generational, effects
on disease risk among AA through epigenetic mechan-
isms [32]. At the least, it seems likely that such effects
exerted in childhood can cause a child to embark on the
road to eventual cardiovascular disease [28].
The endothelial cell
The vascular endothelial cell is a universal participant in
vascular diseases, and for that matter in many “non-
vascular” diseases, for example, immune and infectious
inflammatory diseases. Therefore, the endothelial cell
could be an executor in fulfilment of any potential influ-
ence of genomic effects relevant to health discrepancies.
Indeed, the endothelial cell is unique in being a critical
participant in, and regulator of, multiple vascular func-
tions, as well as comprising the major biological linkage
between them. Examples include inflammation biology,
governance of the pro- versus anti-coagulant balance,
and regulation of vascular tone, among others. These
processes and their proximate regulatory mechanisms
interact in complex ways, so the functional/physiologic
impact of even a precisely known allelic association is
not necessarily accurately predictable. Hence, verifica-
tion of genomic implications on cell biology is of vital
importance for understanding pathophysiology, and
such information can reveal therapeutic options and
even inform pharmaceutical development.
Regarding vascular disease, AA exhibit a variety of
findings consistent with endothelial dysfunction, in par-
ticular abnormal nitric oxide(NO)-dependent vasorelaxa-
tion [33,34]. Consistent with this, ethnicity affects
prevalence of clinically relevant variants of endothelial
nitric oxide synthase (eNOS) [35]. Also, cultured umbili-
cal cord endothelial cells from AA babies revealed hints
of eNOS malfunction (uncoupling) [36].
Rationale
The present study reflects our overarching interest in
the concept that genetically-influenced, inter-individual
differences in endothelial cell biology contribute to the
heterogeneity of clinical phenotype evident in vascular
diseases. As a general concept relating genomics and
health, this is an accepted and compelling model for
complex diseases. Regarding endothelial biology specifi-
cally, we previously employed the present approach to
reveal gene expression differences coincident with a cor-
responding exaggerated endothelial cell response to
inflammation signaling among the subgroup of children
with sickle cell anemia who develop arterial occlusive
disease in the Circle of Willis at the base of the brain
[37]. Similarly, the present study was enabled by the
technology we previously devised [37] that allows pro-
duction of robust cultures of reporter endothelial cells
(BOEC, blood outgrowth endothelial cells) from periph-
eral blood obtained from specific, phenotypically-defined
individuals, in the present case, those self-identified by
race as being AA or CA. We chose this device for sub-
ject group assignment because it was the method used
for seminal epidemiologic studies of stroke and hyper-
tension prevalence among AA [2,3], and we wished the
present results to be directly relevant to such studies.
Caveats regarding this approach for subject group
assignment, as well as the very concept of race, are pre-
sented in the Discussion.
Methods
All aspects of this study were performed with the
approval of and monitoring by the Institutional Review
Board at the University of Minnesota and were in com-
pliance with the Helsinki Declaration.
Subjects
Eligible volunteer subjects were between 20 and 29 years
of age, inclusive, because we wanted our study to focus
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be healthy, to not have any known cardiovascular dis-
ease, and to not be taking heart or lipid-lowering or
blood pressure medications. We chose subjects who
self-identified as being CA or AA, and they were
included only if they stated that both parents were also
CA or AA, respectively. In Minnesota, CA are overwhel-
mingly of European origin, largely from central and
northern Europe. We excluded potential subjects who
were from coastal East Africa for two reasons. First, the
significant influx of East Africans to the upper Midwest
has been a recent phenomenon, largely occurring after
the seminal studies of AA cardiovascular health dispar-
ity, including the one done locally. Second, the gene
pool in East Africa differs somewhat from that of Cen-
tral/West, sub-Saharan Africa (the ancestral origin of
most African Americans), as evidenced by the former’s
low frequency of Duffy negative status and virtual
absence of the sickle mutation [17-19].
Of the 45 subjects providing blood samples for this
study, we subsequently excluded three AA and four CA
because their BOEC cultures failed quality control test-
ing (see below). The remaining 38 subjects (12 AA
males, 9 AA females, 8 CA males, and 9 CA females)
were grouped to create two subject groups, AA (n = 21)
a n dC A( n=1 7 ) .T h eA Ag r o u pi n c l u d e dt w oi n d i v i -
duals with sickle trait (tested for on each subject), the
expected prevalence, but none with sickle cell anemia.
Endothelial culture (BOEC, blood outgrowth endothelial
cells)
Subjects donated 50 to 100 ml of citrated peripheral
b l o o dt h a tw ei m m e d i a t e l yu s e dt oo b t a i np e r i p h e r a l
blood mononuclear cells that were then placed in a
special culture system (on collagen I; with multiple
endothelial growth factors) [38]. The outgrowth BOEC
from this long-term culture are mature, fully differen-
tiated endothelial cells having unambiguous identity (by
phenotypic, functional, gene expression, and electron
microscopic criteria); and their population uniformity
(100% BOEC) has been established [38-41]. Although
BOEC cultures ultimately reach approximately 10
18-fold
expansion [38], for the present study cells were expanded
only to approximately 3 × 10
7 cells (representing
approximately 10
6-fold overall expansion). BOEC were
harvested four hours after the last change of culture med-
ium and when they were 85 to 90% confluent. Each cul-
ture was meticulously performed by the same, highly-
trained individual, ensuring that each step was always
executed in the same manner. Culture medium compo-
nents were obtained prior to project onset so that the
same lot of reagents could be used for all cultures in this
study. Aliquots of BOEC were taken for experimental
use, quality control tests, and for cryopreservation.
Our quality control protocol is to verify that BOEC
cultures are morphologically endothelial (cobblestone),
t h a tt h ec e l l sa r ep o s i t i v ef o rt h r e ee n d o t h e l i a lm a r k e r s
(CD31, VE-cadherin, P1H12), and that the cells are
negative for monocyte/myeloid markers (CD14, CD45)
as well as a probable marker of endothelial progenitor
cells (CD133). We obtain cytogenetics analysis on each
culture to ensure the BOEC are not characterized by
culture-acquired clonal chromosomal abnormalities.
Failure to meet the latter criterion is the reason seven
subjects were excluded from data analysis.
Importantly, BOEC are not the so-called “EPC” that
have been repeatedly (and largely erroneously) described
in the literature. Rather, they are the progeny of a circu-
lating, marrow-derived, transplantable, true endothelial
progenitor cell [38]. Thus, BOEC themselves have never
been influenced by in vivo m o d i f i e r ss u c ha sb l o o d
milieu or tissue-specific signaling. Unlike other endothe-
lial types, BOEC retain their phenotype at high degrees
of expansion. Since they cryopreserve very well, aliquots
from these cultures were saved at time of harvest for
potential, future follow-up studies. Our previous valida-
tion studies of the present methods demonstrated that
harvesting of BOEC at the degree of expansion used
here takes place within a broad and safe window in
which genetic instability has not ensued, but acquired
endothelial phenotypes would have disappeared [37].
Microarray method
Sample preparation utilized BOEC trizol lysates and
was always performed by the same individual and
exactly as previously described [37]. For this study we
used the Affymetrix U133A chip (Santa Clara, CA,
USA). because our extensive prior validation experi-
ments were performed using it. Biotin-labeled cRNA
fragment samples were turned over immediately to our
Microarray Core Facility which then returned raw data
to us for analysis. To eliminate a source of variability,
we purchased one single lot of chips in sufficient
quantity for all samples from this project, so there
would be no effects due to different lots of chips. We
used the robust multiarray average (RMA) method to
summarize expression values [42]. Data were back-
ground-adjusted, quantile-normalized (global scaling),
and expression measures were summarized based on
log-transformed perfect match values using median
Polish algorithm. Then, we used locally weighted scat-
ter-plot smoothing (LOWESS) to perform within-array
normalization [43]. RMA and LOWESS smoothing
were implemented in the software Genedata Expressio-
nist Pro3.1PP (Basal, Switzerland).
Microarray data from this study have been deposited
at the Gene Expression Omnibus, National Center for
Biotechnology Information: GEO accession GSE22688,
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Analysis of single gene expression
To test for differential expression of single genes, we
utilized three approaches. (a) The Welch t-test does not
require that variances of expression levels between two
groups are equal, but it does assume that they are nor-
mally distributed [44]. The resulting P-value needs to be
corrected for multiple comparisons, but a full Bonfer-
roni correction is believed to be far too stringent for
application to microarray data. (b) Significance Analysis
of Microarray (SAM) is a nonparametric statistical pro-
cedure that employs False Discovery Rate (FDR), and it
estimates FDR as an expression of false positive rate
[45]. FDR is advantageous because it already adjusts for
multiple hypotheses testing [46]. In this study, tran-
scripts with FDR <.05 were considered to be signifi-
cantly differentially expressed. However, to filter for a
smaller field of transcripts, the results we focus on here
used the much more highly stringent requirement that
FDR = 0. (c) In addition, we simply examined the fold
change of single gene expression for AA versus CA sub-
ject groups. All analyses of single gene expression were
carried out in the statistical software R [47]. Specifically,
we used the R function t-test for the Welch t-test and
the R package samr for the SAM and fold change
analyses.
Positive internal control and power calculation for
analysis of single gene expression
As a positive internal control, we tested the 20 male and
18 female subjects for expression of selected genes. For
the male group, 11/11 Y-linked genes showed signifi-
cantly higher expression in the BOEC from male donors
(FDR = 0). For the female group, 17/17 X-linked genes
showed significantly higher expression in the BOEC
from female donors (FDR = 0). Thus, SAM analysis
robustly provided the correct answer.
To estimate the power of this study to detect differen-
tial expression of single genes, we performed a power
calculation, assuming the requirement for a significance
was P =1 0
-5, equivalent to P = .05 corrected for 5,000
multiple comparisons. The software Java Applets for
Power and Sample Size [48] was employed for power
analysis for two-sample t-test. Microarray data from 27
BOEC samples from a previous study [37] were used to
obtain the expected levels of expression and variance for
this estimate. This estimated the power for detecting
1.5-fold differences to be 100% for transcripts at all
quartile levels of expression. Power for detecting a 1.25-
fold difference was (from highest to lowest expression
levels): 100%, 90.5%, 64.1%, 32.9% and 67.8%.
Analysis of biological systems differences
Examination for differences between study groups in
terms of biological systems pattern employed predeter-
mined gene sets. Their construction took place prior to
onset of this study, as described elsewhere in greater
detail [37,43], and was based on a variety of databases,
as well as our review of the relevant literatures. These
gene sets are not mutually exclusive, as we wanted them
to broadly survey each given biological system, and
these systems overlap biologically. For example, the
shear stress responsive set includes members of multiple
other biologies but which have in common shear
responsiveness (see Discussion). The biological systems
(number of members in a gene set) were: adhesion
(146), angiogenesis (131), apoptosis (79), coagulation
(152), hypoxia response (109), inflammation (117), redox
signaling (83), shear stress response (156), and vasoregu-
lation (106). The precise composition of these system-
oriented gene sets is available elsewhere [49].
To determine whether pre-defined gene sets identified
significant biological system differences between AA and
CA, we utilized Gene Set Enrichment Analysis (GSEA).
This test ranks individual genes in the set on the basis
of t-statistic, examines for enrichment (in direction of
either higher or lower expression) concordant with sub-
ject group assignment, and conducts many permutations
to estimate the empirical nominal P-value and the FDR
q-value, an expression of false positivity likelihood [50].
A gene set with FDR <.25 was considered significant, as
suggested by the method’s originators, and we tested
our dataset in GSEA Java desktop software V2.0 which
was downloaded from the authors’ website [51].
Negative internal control and power estimate for analysis
by GSEA
As a (potential) negative internal control for the GSEA
analysis of the nine biological systems, we utilized gen-
der as a virtual biological system and compared the 20
males to the 18 females. As expected, neither P-value
nor estimated FDR were significantly different for any of
the nine systems for these two groupings (data not
shown).
Since there is no (known) way to perform a power cal-
culation for GSEA analysis, we conducted multiple
simulations in the statistical software R [47], based on
the effect size and variance estimates from 27 BOEC
samples from a previous study [37]. Simulation-based
power estimation [52] is a generic approach and suitable
for non-standard statistical techniques, such as GSEA.
These allowed us to estimate that power of identifying
significant changes for our pre-determined biological
system gene sets (that is, P < .05 and FDR <.25) in this
study approaches 100%.
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T h i sw a su s e dt ov e r i f yg e n ee x p r e s s i o nb yB O E Cf o r
authentic PSPH and the PSP-homolog (PSPHL), SOS1,
AMFR, HSGP25L2G, Cxorf12,a n dEIF4B.T h e s ew e r e
chosen for qRT-PCR analysis because of their rank in
the fold-change assessment for single gene differences.
Primers and probes are displayed in Additional File 1.
Methods were standard and were performed by the
same individual, as previously described [37].
Phosphoserine phosphatase activity
Previously cryopreserved BOEC from all of the subjects
were re-established in culture. BOEC at 90% confluence
were harvested for whole cell lysate preparation in
phosphate-free buffer using three freeze-thaw cycles.
L-phosphoserine phosphatase activities were measured by
the release of inorganic phosphate (Pi) from L-phosphoser-
ine, using an assay somewhat modified from that of Cho
et al. [53]. The method is described in greater detail in
Additional File 2. The phosphatase activity of each sample
was expressed as μmol Pi/μg protein in total cell lysate. We
utilized the same method to assess in vitro activity against
substrate L-phosphoserine of authentic PSP (obtained from
abcam, Cambridge, MA, USA) and PSP-homolog (synthe-
sized in the Oligonucleotide and Protein Synthesis Facility
in our Biomedical Genetics Center core facility).
Results
Single gene expression
Analysis by FDR-based SAM
Comparison of BOEC from AA versus CA demonstrated
that 31 genes were differentially expressed by the two
groups when we employed the highly stringent require-
ment that FDR = 0. As shown in Table 1, the expression
of four genes was increased in AA compared to CA,
while expression of 27 genes was lower in AA. (Note
that entries in Table 1 are ranked in order of numerical
fold-change, so those with the greatest up-regulation are
at the top, but those with the greatest down-regulation
are at the bottom.)
Using the more customary, and less stringent, filter
requiring only that FDR <.05, we identified for AA com-
pared to CA: 21 transcripts representing 20 up-regulated
genes, and 200 transcripts representing 184 down-
regulated genes (see Additional File 3 and Additional
File 4, respectively).
Analysis by t-test
Each of these Tables additionally displays the results of
testing for significance using the Welch t-test. As shown
i nT a b l e1f o rg e n e sw i t hF D R=0 ,t h es a m e4g e n e s
identified by FDR for AA > CA, and 15 of the genes
identified for AA < CA, additionally have P < 10
-4. Since
different investigators prefer different stringencies of
Bonferroni correction, we display the raw P-values.
Analysis by fold-change
Fold-change in expression (expressed as AA/CA) is also
shown in each Table. In Table 1 the four up-regulated
genes with fold-change approximately 1.25 or greater
(PSPH, SOS1, AMFR, and FGFR3) and the two stron-
gest, equivalently (fold change ≤.80) down-regulated
genes (EIF4B, CXorf12) are most noteworthy.
Phosphoserine phosphatase, Affymetrix “PSPH”
Of the genes shown in Table 1, “PSPH” stands out because
it exhibits the highest differential expression among
AA subjects (4.08-fold increase, FDR = 0, P =4×1 0
-9)
(Figure 1A). However, only two of the Affymetrix probes
for PSPH are specific for authentic PSPH, while the others
additionally detect the known homolog, PSPHL.I n d e e d ,
qRT-PCR revealed that expression of authentic PSPH was
not significantly different for AA versus CA, and it was
very modest (Figure 1B). In contrast, expression of PSPHL
was significantly elevated (P = .015) for the AA subjects
(Figure 1C), and this entirely accounts for the false positive
array result for PSPH. Interestingly, qRT-PCR analysis
showed that PSPHL was undetectable in 12/17 CA donors
but only 1/21 AA subjects.
The homolog, PSPHL, has partial sequence identity to
PSPH, and the 31-residue overlap region contains some,
but not all, of those involved in substrate hydrolysis [54,55].
The PSPHL product is thus unlikely to display enzymatic
activity. Consistent with published data [54], authentic PSP
exhibited half-activity on L-phosphoserine at 2 μM, while
the PSP-homolog had no activity. To screen for possible
inhibitory activity by the homolog, we examined the
L-phosphoserine phosphatase activity of AA versus CA
BOEC. Despite PSPHL having higher levels in AA BOEC
(Figure 1C), the L-phosphoserine phosphatase activities of
BOEC from AA and CA were equivalent: 1.16 ± 0.22 and
1.21 ± 0.31 μmole Pi/μg total cell lysate, respectively. The
amount of endogenous free Pi in AA BOEC (2.80 ± 0.77
μmole Pi/μg) was slightly, but not significantly, higher than
in CA BOEC (2.29 ± 0.93 μmole Pi/μg).
qRT-PCR
We used qRT-PCR to examine (previously-cryopre-
served) BOEC from all study subjects for expression of
several genes from Table 1, and fold-changes were 1.26
for authentic-PSPH (P =N S )a n d3 . 9 6f o rPSPHL (P =
.0154) for AA versus CA. As predicted from the small
fold-changes detected by microarray, qRT-PCR was
unable to confirm a significant difference for the gener-
ally similar fold-changes for SOS1, AMFR, HSGP25L2G,
Cxorf12,o rEIF4B.
Biological systems analysis
To consider whole biological systems relevant to
endothelial biology, we used GSEA to test BOEC from
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tems tended to have altered expression: adhesion, apop-
tosis, angiogenesis, coagulation, hypoxia response,
inflammatory signaling, redox response, shear stress
response, and vasoregulation [37,49]. This comparison
revealed a significant whole-system differential expres-
sion in one biological system, shear stress response
genes. This was evidenced not only by P = .027 and
FDR = .14, but also by the fact that these indicators are,
s i m p l yb yi n s p e c t i o n ,u n a m b i g u o u s l yd i f f e r e n tf r o mt h e
values for the other eight systems (Table 2). The com-
ponent composition of the shear response gene set is
provided in Table 3 which also indicates which mem-
bers of this set actually contributed to identification of
this particular biological system as being different for
AA versus CA (that is, those exhibiting “core enrich-
ment”). The expanded names of these gene identifiers
are provided in Additional File 5. All genes within the
core enrichment group were found to have changed in
direction of increased expression.
Discussion
We here examined whether, at the level of gene expres-
sion, there are detectable endothelial cell differences
Table 1 Single gene differences (at FDR = 0) by BOEC from AA (n = 21) versus CA (n = 17)*
Affymetrix
ID
Gene
Name
FDR Fold Change
(AA vs CA)
Welch t-test
(P)
Gene Description
205048_s_at “PSPH”
‡ 0 4.08 4 × 10
-9 Phosphoserine Phosphatase
212777_at SOS1 0 1.36 1 × 10
-7 Son of Sevenless Homolog 1
202203_s_at AMFR 0 1.72 4 × 10
-6 Autocrine Motility Factor Receptor
204379_s_at FGFR3 0 1.24 2 × 10
-5 Fibroblast Growth Factor Receptor 3
219417_s_at FLJ20014 0 0.91 6 × 10
-5 Chromosome 17 Open Reading Frame 59
208416_s_at SPTB 0 0.91 1.9 × 10
-4 Spectrin, Beta, Erythrocytic
206763_at FKBP6 0 0.90 6 × 10
-5 FK506 Binding Partner 6, 36 kDa
202253_s_at DNM2 0 0.90 2.3 × 10
-4 Dynamin 2
214380_at PRPF31 0 0.90 9 × 10
-5 Precursor mRNA-processing Factor 31, S. Cerevisiae, Homolog of
213209_at TAF6L 0 0.89 8 × 10
-7 TAF6-like RNA Polymerase II, p300/6CBP Associated Factor (PCAF), Associated
factor, p65
216204_at ARVCF 0 0.89 4 × 10
-6 Armadillo Repeat Gene Deletes in Velocardiofacial Syndrome
213585_s_at PDCD2 0 0.89 3 × 10
-5 Programmed Cell Death 2
201572_x_at DCTD 0 0.89 2.1 × 10
-4 Deoxycytidylate Deaminase
203589_s_at TFDP2 0 0.89 3.3 × 10
-4 Transcription Factor DP-2 (E2F Dimerization Partner 2)
211096_at PBX2 0 0.88 3 × 10
-6 Pre B-cell Leukemia Transcription Factor 2
215844_at TNPO2 0 0.88 8 × 10
-5 Transportin 2
206182_at ZNF134 0 0.88 2.3 × 10
-4 Zinc Finger Protein 134
219125_s_at LOC55974 0 0.87 2 × 10
-5 Stromal Cell Protein
201557_at VAMP2 0 0.87 6 × 10
-5 Vesicle-associated Membrane Protein 2 (Synaptobrevin2)
202700_s_at KIAA0792 0 0.87 1.3 × 10
-4 Transmembrane Protein 63A
209009_at ESD 0 0.87 2 × 10
-4 Esterase D
200076_s_at MGC2749 0 0.86 3 × 10
-5 Hypothetical Protein MGC2749
207415_at PLA2R1 0 0.86 2 × 10
-5 Phospholipase A2 Receptor 1, 180 kDa
222129_at C2orf17 0 0.86 1.6 × 10
-4 Chromosome X Open Reading Frame 17
202646_s_at D1S155E 0 0.85 1.1 × 10
-4 Cold-shock Domain-containing E1, RNA-binding; CSDE1
222199_s_at BIN3 0 0.85 7 × 10
-5 Bridging Integrator 3
219939_s_at D1S155E 0 0.82 1 × 10
-4 Cold-shock Domain-containing E1, RNA-binding; CSDE1
203538_at CAMLG 0 0.82 7 × 10
-4 Calcium-modulating Cyclophilin Ligand
208757_at HSGP25L2G 0 0.81 1 × 10
-6 GP25L2 Protein
218354_at LOC51693 0 0.81 3.5 × 10
-4 Hematopoietic Stem/progenitor Cells 176
204340_at CXorf12 0 0.77 2 × 10
-4 Chromosome X Open Reading Frame 12
219599_at EIF4B 0 0.76 4 × 10
-5 Eukaryotic Translation Initiation Factor 4B
*This table shows only those genes that meet the very high stringency level of FDR = 0 by SAM (Significance Analysis of Microarray). Genes are ranked by fold
change (AA versus CA) so that those with the greatest up-regulation are at top of the list, but those with the greatest down-regulation are at the bottom. All
transcripts exhibiting higher expression in AA versus CA subjects, using the less stringent significance threshold of FDR <.05, are shown in Additional File 3 (n =
21 probe sets, representing 20 genes). Likewise, all transcripts exhibiting lower expression in AA versus CA subjects at FDR <.05 are shown in Additional File 4
(n = 200 probe sets, representing 184 genes).
‡ This gene designation from Affymetrix is incorrect - see Figure 1.
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impact on the biology of the vessel wall such that risk
for vascular disease would be influenced. The present
results indicate that the endothelial expression of a
number of genes does differ for AA versus CA, and the
biological system of shear stress responsiveness is differ-
ent for AA as well. The high relevance of these observa-
tions to endothelial biology is discussed below. But in
summary, the present results support the notion that
genetically-determined differences in endothelial gene
expression (determined by ancestral continent of origin)
can influence vascular wall biology and, therefore,
impact on vascular disease risk. Moreover, this study
illustrates the feasibility of utilizing this method to help
bridge the gap between structural information provided
by genomics and the consequent impact upon cell biol-
ogy and pathophysiology.
To accomplish our goal we took advantage of a
unique source of endothelial reporter cells, BOEC,
which have never been influenced by in vivo signalling,
for example, by the plasma milieu or tissue-specific fac-
tors. Therefore, their phenotype is influenced only by
culture conditions and the genetic composition of the
BOEC donor. Since the cultures are performed meticu-
lously and are controlled fastidiously, we believe that
this method can preliminarily identify potential, geneti-
cally-influenced differences in endothelial cell biology.
A previously reported example of this approach is noted
in the Introduction, and it describes the methods valida-
tion that was conducted for both BOEC cultures and
specific application of microarray profiling to them [37].
Since BOEC, unlike other endothelial sources, cryopre-
serve well they can be banked at time of initial culture
harvest and be saved for confirmatory future examina-
tion by cell biologic or other methods in studies that
have been informed by the gene expression results.
Single gene expression
We detected 31 genes that met our most stringent cri-
terion for differential expression significance, that FDR
= 0, with 4 changed in the AA > CA direction, and
27 changed in the AA <CA direction (Table 1). All tran-
scripts that showed a significant degree of change at the
much more commonly utilized threshold of FDR <.05
are displayed in Additional File 3 (21 transcripts for
20 genes for AA >CA) and Additional File 4 (200 tran-
scripts for 184 genes for AA <CA).
PSPH and PSPHL
“PSPH“ was differentially expressed (AA >CA) at highest
fold-change. However, this was fully accounted for by
elevated expression of the known homolog, PSPHL
(Figure 1), which exhibited no activity either as a
L-phosphoserine phosphatase or as an inhibitor thereof.
No studies have examined it for the possibility of other
Figure 1 BOEC expression of PSPH, authentic-PSP (PSPH), and PSH-homolog (PSPHL). PSPH is the proper gene designation for the
L-phosphoserine-phosphatase gene. Its expression per the Affymetrix U133A chip (probest 205048_s_at) seems to show elevation for AA (panel
A). However, when authentic PSPH is measured by qRT-PCR, no difference for between groups is found (panel B). Rather, the elevation detected
by microarray (panel A) is fully accounted for by increased expression (P = .015) of the PSP-homolog, PSPHL, in AA >CA (panel C). By qRT-PCR,
expression of PSH for 1/21 AA and for 12/17 CA samples was undetectable.
Table 2 GSEA results for nine biological systems,
comparing AA versus CA*
Biological System Gene Set Size Nominal P FDR
Adhesion 146 0.907 .100
Angiogenesis 131 0.960 .946
Apoptosis 79 0.202 .551
Coagulation 152 0.416 .815
Hypoxia 104 0.547 .780
Inflammation 117 0.989 .987
Redox 83 0.788 .932
Shear stress 156 0.027 .140
Vasoregulation 101 0.822 .920
* For GSEA (Gene Set Enrichment Analysis), FDR <.25 is considered to be
significant (see Methods). Construction and specific composition of gene sets
has been presented elsewhere [37,49].
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Page 8 of 18biological activities. Nonetheless, since its expression
distributes largely according to self-identification of race
( F i g u r e1 ) ,i tc o n c e i v a b l yi so fi n t e r e s t .I tm a yb eu s e f u l
as a marker of continent-of-origin, and this is the likely
reason that increased PSPHL expression has been noted
in prostate and breast cancers of AA individuals, as well
as specifically in the tumor stroma of breast cancer
[56,57]. Yet, since most CA (12 of 17) in the present
study had no detectable expression of the homolog, the
(unknown) reason that its expression was detectable at
all in most AA (20 of 21) might itself be of interest. To
date, the cell-type restriction, if any, for its expression
has not been reported. It is known that PSPH and
PSPHL reside at different locations: chromosomes 7p
15.1 to 15.2 and 7q 11.2, respectively.
As a caution to investigators, we note that the “PSPH“
Affymetrix 205048_s_at probeset (on both U133A and
U133A 2.0 arrays) actually detects both PSPH and
PSPHL, as described above. This same probeset has
erroneously been labelled PSPHL in at least one pre-
vious report [56], and is erroneously labelled PSPH by
Affymetrix.
Table 3 Shear Stress Biological Gene Set (156 Members)
Gene Contributes to Core Enrichment Gene Does Not Contribute to Core Enrichment
BMP4 SP1 ACTB GJA1 PDPK1
BMP6 TBXAS1 AKAP1 GNAS PECAM1
CCL2 TGFB1 ANXA2 GNB2 PFDN5
CD34 THBD ANXA5 GNG5 PTGS2
CENPF THBS1 APOE GRN RGS5
CTGF TRA1 APS HADHSC RPL30
CXCL12 TUBG1 ARF4L HMOX1 RPL34
CYP1B1 VCAM1 ASS ICAM1 RPS11
CYR61 VIPR1 CAV1 IFITM3 RPS7
DPYSL3 XPO1 CCL15 IL13RA1 SAT
EDN1 CCL25 IL15 SCGF
EEF1A2 CD164 IL16 SELE
ELN CD1D IL1R1 SERPINE1
F3 CD58 IL1RL1 SERPINE2
FGF2 CD68 ITGB3 SLC35F2
FN1 CDKN1A JARID1A SMARCD1
GAPD CEACAM1 JUN SOD2
GBP1 CYP1A1 KLF2 SPARC
GJA5 DKK2 LAMB1 SPTA1
GSTP1 E2F5 LIMS1 SPTAN1
IL8 EDN3 LRP2 STAM
ILK EFEMP1 METAP2 TEK
JAG2 EGR1 MGP TFPI
JUNB EIF4EBP2 MMP1 TGFB1I4
KIF20A EIF4G3 MMP14 THBS4
KLF4 ESM1 MMRN1 TNFRSF1A
LIG3 F2 MYD88 TNFRSF5
MAPRE1 F2R NFKB1 TNFSF8
MATN2 FGF6 NOTCH4 TUBA3
MYC FGFR3 NQO1 TXNRD1
NOS3 FLT1 NUMA1 UNG
PFDN2 FOS OGT VCL
PLAT FOSL1 OLR1 VEGFC
RGS3 FTH1 PBP VWF
RHOA FTL PCQAP WNT2B
RHOB GARS PDGFRA
S100A10 GAS PDGFRB
“Core enrichment” indicates that the corresponding gene is in the subset of genes that contributes most significantly to that biological system’s result using
GSEA (Table 2) in the text. In the table above, entries are listed in alphabetical order. An expanded version of these gene names is available as Additional File 5.
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Many of the genes shown to be differentially expressed
at the thresholds of FDR = 0 (Table 1) and FDR <.05
(Additional Files 3 and 4) have direct relevance to
endothelial cell biology. While we do not wish to over-
state their potential importance, the following discussion
of some from Table 1 (presented in order of their listing
therein) attempts to illustrate possible biological roles.
SOS1
(son of sevenless homolog 1) is a necessary factor in
transduction of angiopoietin I signaling-induced chemo-
kinesis of endothelial cells [58]. AA men and women
tend to initially present with more advanced stages of
prostate and breast cancer [56,57]. Therefore, the possi-
bility that elevated endothelial expression of SOS1,a s
recently found in breast tumor mixed-cell stroma in AA
women [57], could contribute to more exuberant angio-
genesis (see below), critical to tumor growth [59],
should perhaps be tested.
AMFR
(autocrine motility factor receptor) is involved in angio-
genesis, endothelial motility, and increased permeability;
and its secretion by tumor cells is reported to up-regulate
the vascular endothelial growth receptor Flk-1 [60]. It too
showed increased expression in prostate cancers in AA
[56], and a role similar to SOS1 can be considered.
FGFR3
(fibroblast growth factor receptor 3) is induced in lym-
phatic endothelium by its developmental “master switch”
Prox1, and it plays a role in the biology of lymphatics
which are important in inflammation and tumor biology
[61]. AA reportedly present with more aggressive forms
of, for example, breast and prostate cancer [57,62].
DNM2
(dynamin 2) is a GTPase that activates eNOS, is a critical
regulator of vascular tension, and may participate in sig-
naling by one of the vascular endothelial growth receptors
[63,64]. Diminished activity of eNOS among AA would, of
course, have substantial implications for endothelial func-
tion and vascular biology (see Introduction).
TAF6L
(TAF-like RNA polymerase II, PCAF, p65) modulates
chromatin structure via association with histone acety-
lase [65] and is a common cis-element in protein synth-
esis and cell cycle promoters [66].
ARVCF
(Armadillo repeat gene deletes in velocardiofacial syn-
drome) is ubiquitously expressed, and it associates with
cadherins at junctions between cells [67]. Although
binding to the endothelial cadherin (VE-cadherin) is
within its repertoire, its function has not been specifi-
cally examined in endothelial cells; so it is difficult to
predict what effect its diminished expression might have
in these cells.
BIN3
(bridging integrator 3) is involved in actin localization
and signalling [68], and it is ubiquitously expressed.
Although an endothelial role per se for BIN3 has not
been tested, actin plays a role in endothelial mechano-
transduction. Hence, its diminished expression in BOEC
from AA perhaps warrants study, given the altered
expression of shear responsive genes that we observed
in the biological systems approach (see below).
CAMLG
(calcium modulating ligand) is involved in angiotensin II
(AGNII) signaling, and CAMLG interaction with
AGNII-type I receptor is suggested to be a participant
in ANGII vasoregulatory actions [69]. This, of course, is
highly relevant to hypertension.
EIFB4
(Eukaryotic translation initiation factor 4B) is a cofactor
in initiation of protein translation. It is unknown
whether its own diminished expression might conspire
with the unrelated diminished transcription observed
here of multiple other genes among AA (Additional File
4) to impact on endothelial biology by augmenting
translational inefficiency. However, since this presum-
ably would adversely impact the endothelial cell’s
responses to stress such as inflammation or shear, it
seems worth considering.
eNOS
Our results revealed no significant difference between
our study groups in NOS3 expression: AA >CA by 1.31-
fold; t-test P = .071; FDR = not significant. Thus, the
eNOS-related differences observed both clinically and
experimentally (see Introduction) perhaps reflect
acquired changes (e.g., enzyme uncoupling) rather than
alterations in the endothelial expression level of the pro-
tein. As noted above, one such possibility would perhaps
derive from the diminished level of DNM2 presented
above.
Biological systems approach
Our second analysis examined whether any of nine bio-
logical systems relevant to endothelial cell biology would
display a tendency toward altered expression for AA
versus CA. Indeed, on a systems basis, AA had signifi-
cantly altered expression of the gene set representing
the shear response biological system, a major determi-
nant of endothelial phenotype and vascular homeostasis
(Table 2). The component members within this gene set
which contributed to this result are shown in Table 3.
Laminar shear stress induces endothelial “quiescence”
(anti-inflammatory, anti-thrombotic, anti-adhesive, anti-
angiogenic, anti-oxidant, anti-atherosclerotic, and with
optimal vasoregulatory balance), while areas of low or
disturbed shear stress exhibit opposite changes [70-73].
Wei et al. BMC Medicine 2011, 9:2
http://www.biomedcentral.com/1741-7015/9/2
Page 10 of 18This actually is oversimplified, since experimental data
indicate that the induced results also can differ depend-
ing upon whether the flow is pulsatile or oscillatory. In
any case, shear responsiveness is mediated partly by its
induced levels of transcription factor KLF2 (Kruppel-like
factor-2), a “master switch” that regulates perhaps a
third of the approximately 1,000 shear responsive genes.
For example, the 47/156 members of the shear respon-
siveness gene set that accounted for the observed differ-
ence between AA and CA are depicted in Figure 2,
which additionally highlights those that are directly
influenced by KLF2. The genes that share the property
of shear responsiveness actually are participants in mul-
tiple endothelial cell biologies as is summarized in lim-
ited fashion in Table 4. For example, some of the
chemokines that promote development of atherosclero-
tic lesions are shear responsive [74], for example, CCL2
(monocyte chemoattractant protein 1) which is one of
the genes contributing to the present implication of
shear responsiveness (Table 3). Notably, KLF2 and
NFB down-regulate each other as significant regulators
in orchestrating endothelial inflammatory phenotype.
The present study cannot identify whether the changes
observed for AA would yield a net beneficial or net harm-
ful effect on vessel wall biology, or whether they would
even alter biological shear responsiveness. The increased
expression among AA was inexplicably observed for genes
that, in the normal process of establishing a quiescent
endothelium, both increase in response to KLF2 (for
example, NOS3, PLAT, THBD) and decrease in response
to it (for example, EDN1, F3, TGFB1, JUNB, VCAM1)
(Table 3, Figure 2). The explanation for this is not known
at this time. Interestingly, there was no concurrent differ-
ential expression of the two major shear response “master
switches,” KLF2 (fold-change 1.05, P = .646, FDR = .678)
or Nrf2 (1.06-fold change, P = .408, FDR = .588). However,
we emphasize that the present method would be insensi-
tive to, for example, a KLF2 SNP that alters its function
but not expression.
Yet, this dilemma may derive, in part, from the fact
that BOEC in this study perhaps would have had a
relaxed shear response system, as opposed to a shear-
modulated one. Unfortunately, existing shear responsive-
ness studies are not very enlightening regarding this
concept because they generally have described changes
induced by a shear regime rather than possible inter-
individual differences in the starting phenotype. We
speculate that the present data, in suggesting a tonic
increase in multiple shear responsive genes for AA sub-
jects, may be hinting at some underlying, functional var-
iation of the apparatus that senses shear stress and
induces phenotypic changes. We emphasize, however,
that there is no direct evidence for this at the present
time. Shear responsiveness is complex, incompletely
understood, and involves multiple steps: mechanosensi-
tivity, trans-membrane mechanotransduction, chemical
mechanotransduction, downstream signalling and feed-
back loops, and ultimately transcription and translation
[70]. We are currently utilizing the banked, cryopre-
served BOEC from the AA and CA subjects in the pre-
sent study to examine their gene expression shear
responsiveness in a flow chamber system, and also to
further delineate reason(s) for any difference.
Integration of results and disease biology
The importance of the endothelial cell in disease biology
cannot be overstated. It resides at the physical and func-
tional interface between blood and tissue and somehow
integrates the input from a panoply of biological modi-
fiers. Some of the physiological processes regulated by
t h e s ec e l l sa r en o t e di nt h eI n t r o d u c t i o n .B e y o n dt h e
conclusions and speculations already presented, we can-
not say exactly how the observed gene expression
changes, if present in vivo in AA, actually impact upon
vascular biology. However, the potential ways in which
genetically-influenced heterogeneities in endothelial
biology could impact on disease genesis are endless. The
present implication of shear responsive genes is particu-
larly interesting, given the fundamental role that this
biological system plays in vascular homeostasis. In parti-
cular, it is directly relevant to the problem of hyperten-
sion in AA, the disease process that is the most likely
candidate to reside proximate to the other vascular pro-
blems. Interestingly, this biological system is particularly
amenable to influence by gene-environment interaction.
Its functional integrity is susceptible to the confluence
of effects of salt, lipids, arterial wall stiffening, oxidation
biology, endothelial dysfunction and disturbance of
vasodilators and vasoconstrictors.
Specific examples of dietary salt and lipid influences
were noted in the Introduction. Emerging data empha-
size the common occurrence of cardiovascular disease
despite an absence of customary risk factors and suggest
the importance of coincidental concurrence of genetic
variability (genetic high risk) and environmental factors
such as tobacco smoke exposure (environmental high
risk) in premature and/or accelerated disease genesis
[30]. An illustrative example of this in the general popu-
lation, inherited variation in APOE alleles, is provided
by the large role that oxidative stress probably plays in
cardiovascular disease genesis. Compared to the majority
of individuals having the ε3 isoform (gene frequency
approximately 0.77), the fewer individuals having the ε2
isoform (gene frequency approximately 0.08) have the
highest levels of blood APOE and lower cholesterol
levels and protection from cardiovascular disease and
stroke. Conversely, those with the ε4 isoform (gene fre-
quency approximately 0.15) have the lowest APOE levels
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Page 11 of 18Figure 2 KLF2 connections to 47 genes contributing to shear responsive biological system result. The relationship of transcriptional
regulator KLF2 to each of the 47 genes contributing to the difference in the shear responsiveness biological system is shown here. KLF2 up-
regulates genes shown in magenta and down-regulates those shown in blue. Genes shown in yellow are not directly regulated by KLF2. Genes
shown in white are not members of the shear responsive gene set but are linkers extant in the displayed relationships. This figure was
constructed via access to Ingenuity Systems, Inc.
® [87]
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Page 12 of 18Table 4 Shear stress biology genes contributing to core enrichment: spectrum of vascular biological functions
Cell Migration Angiogenesis and
Vascularization
Vasomotor Immune
System
Chemotaxis,
and so on
Hemostasis and
Hematologic
Gene name
BMP4 XX X X X
BMP6 XX
CCL2 XX X X
CD34 XX X
CENPF
CTGF XX
CXCL12 XX X
CYP1B1 XX
CYR61 XX X X
DPYSL3 X
EDN1 XX X X
EEF1A2
ELN XX
F3 XX X X
FGF2 XX X
FN1 XX X X X
GAPD XX
GBP1
GJA5 XX X
GSTP1
IL8 XX X X X
ILK XX X X
JAG2 XX
JUNB XX
KIF20A
KLF4 XX X
LIG3
MAPRE1
MATN2 X
MYC XX X X
NOS3 XX X X X
PFDN2
PLAT XX X X
RGS3 X X
RHOA XX X X
RHOB X
S100A10 XX X
SP1 XX X X
TBXAS1 XX X X
TGFB1 XX X
THBD XX
THBS1 XX X X X
TRA1 X
TUBG1
VCAM1 XX X
VIPR1 X
XPO1
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tion observed for ε4 individuals is largely seen in those
having environmental exposure to tobacco smoke [30].
Furthermore, the antioxidant capability of APOE shows
apoE2 > apoE3 >apoE4, and the latter individuals exhibit
higher levels of lipid hydroperoxides, which are harmful
to endothelium [30]. In linking genetic makeup with
dietary habits and environmental exposure, this provides
a dramatic example of gene-environment interaction
and the contextual complexity of its role as a determi-
nant of vascular disease phenotype. As noted elsewhere:
‘Genes load the gun, but the environment pulls the trig-
ger’ (attributed to Dr. Elliot Joslin) [30].
Finally, as noted in the Introduction, health disparities
occur worldwide and in many forms. Undoubtedly,
some reflect mostly environmental/social factors and
others are more dependent upon genetic factors. How-
ever, a genetic admixture at some level is a universal
characteristic of the human population, so the present
study is widely relevant in the general sense. Admixture
mapping studies for disease association loci are in the
earlier stages of development, so at this time they are
applied to more dramatic cases of genetic admixture in
populations. One example, derived from an admixture a
few hundred years (approximately six to seven genera-
tions) ago, is described here. Another prominent admix-
ture occurred in western China, where the Uyghurs
display an approximately 50/50 admixture of Asian and
European backgrounds [75]. This example occurred
more remotely, perhaps approximately 100 generations
ago, and is likely explained by the fact that the Uyghurs
have lived astride the historical Silk Road. Therefore, it
most likely represents a version of admixture that is
more historically representative of the human experi-
ence, admixture accompanying commerce or migration.
The endothelium in cancer biology
Quite separately from cardiovascular health, endothelial
cells play a fundamental role in cancer biology since
tumor growth is rate-dependent on angiogenesis [59].
AA are known to have cancers (for example, of prostate
in men [56,62] and breast in women [57,76]) that exhi-
bit greater aggressiveness, present in more advanced
stages, and entail higher mortality rates, compared to
their behavior in CA. Of great relevance to the theme of
the present study, an examination of breast tumor
microenvironment suggested that it exhibits a greater
degree of angiogenesis (largely a host response to tumor
presence) in AA compared to CA [57]. And in the gen-
eral population, increased likelihood of invasive and
metastatic breast cancer (previously shown to be influ-
enced by the degree of tumor angiogenesis) is associated
with specific vascular endothelial growth factor alleles
[76], as is the aggressiveness of prostate cancer in men
[62]. Therefore, the approach used in the present study
may well be of use to further identify the influences of
genetics and continent-of-origin on the endothelial biol-
ogy of angiogenesis insofar as it contributes to cancer
cell behavior.
Caveats regarding this study
Self-identification of race and genetic admixture
R a c ei ss t r i c t l yas o c i e t a lc onstruct based on awareness
of superficial traits, but it has been used for (presump-
tively) identifying continent-of-origin ever since genetic
considerations began being applied to humans. Although
self-identification of race is hazardous in societies that
have high degrees of both diversity and genetic admix-
ture (for example, Brazil [77]), within the United States
excellent correspondence between self-reported race/
ethnicity and genetic markers reflecting ancient geo-
graphic ancestry has been observed [78].
On the other hand, a genetic admixture of individuals
having different ancestral origins is the major determi-
nant of genetic structure in the United States [78].
Thus, an admixture of European and African genetic
backgrounds over six to seven generations has resulted
in the average African American having approximately
20% European admixture [79,80], although on an indivi-
dual basis this ranges widely from approximately 5% to
approximately 70% [80]. The African origin component
is almost entirely from West and West-Central, sub-
Saharan Africa [79]. In our region of the United States,
the Upper Midwest, reported degrees of admixture are
similar, for example, approximately 19% for Chicago and
approximately 16% for Detroit [80,81]. The level of
admixture in the opposite direction, African into
European, is estimated to be about 0.4% [80].
T h ed e g r e eo fa d m i x t u r ei nA Ap r o b a b l ye x e r t sa n
impact upon development of disease, as revealed by the
expanding use of admixture mapping [82]. In turn, one
should expect that variation in degree of admixture
could exert an influence upon endothelial gene expres-
sion, as studied here, and upon endothelial function, as
implied by the present studies. However, insofar as
African origin accounts for the differences observed
here, the effect of admixture on present results would
be in the direction of diminishing the difference
between the AA and CA. In other words, differences in
endothelial gene expression reflecting continent-of-ori-
gin are observed here despite any diluting impact of
admixture. That the degree of admixture for the present
subjects is unknown should not be an issue, since the
very point of this study was to examine AA subjects
sampled in the same fashion they were for the seminal
studies demonstrating that, despite undefined individual
degrees of admixture, the AA sub-population has higher
level of stroke and hypertension [2,3].
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ductively employed to study the endothelial features of
subjects who were specifically selected for their known
and defined degree of admixture(s).
Absence of detailed medical information
The 20- to 29-year-old subjects selected for this study
claimed cardiovascular health, and incidentally were
not obese. We did not examine them for risk factors
such as BMI, blood lipid levels, fasting glucose, hyper-
tension and so on. However, as for the preceding sec-
tion, that was the point of this first study. Without
pre-study bias due to knowing such information, we
obtained the present results. We again note that our
approach could be utilized to study subjects known to
have specific disease risk variables, and specific per-
turbing influences of interest (for example, oxidized
lipid) could thereby be examined in vitro in a known
genetic context.
Are “young and healthy” subjects really healthy?
Consistent with the preceding paragraphs, the intention
of this study was to examine AA who were “young and
healthy” in the sense that they would be so judged dur-
ing a visit to a medical clinic, prior to conduct of any
medical history, examination, or testing. Indeed, statisti-
cal divergence of the higher AA prevalence of first myo-
cardial infarction (the gold-standard clinical indicator of
underlying vascular disease) does not emerge until the
35 to 44 age range [8].
On the other hand, the situation for those <35 years is
more an absence of evidence rather than evidence of
absence. Indeed, it is notable that onset of some cardiovas-
cular risk conditions prior to adulthood has become a fea-
ture of modern society, as evidenced by the epidemic of
obesity among children and adolescents in the United
States. Compared to CA in the same age group, AA adoles-
cents have a lower prevalence of smoking (approximately
13% versus approximately 26%) but a higher prevalence of
an inadequate level of physical activity (approximately 39%
versus approximately 30%), and adolescent AA females,
but not males, have an increased prevalence of obesity
(approximately 24% versus approximately 15%) [83]. In the
general adolescent population, obese children are more
likely to exhibit higher systolic blood pressure [84] and
blood lipid levels [85], and to have type-2 diabetes at
9- and 26-year follow-up visits [86].
Although these data suggest that the “young and
healthy” may not actually be so healthy, the correspon-
dence between many of these risk factors is with obesity.
We are unable to find in the literature the prevalence of
such risk factors for non-obese AA children and adoles-
cents. Nonetheless, the present method offers a way to
actually test the endothelial biology of (genetically- or
clinically-defined) high-risk adolescents, long before they
actually develop clinical cardiovascular disease.
Small number of subjects
The present results were obtained by comparison of a
relatively small number of subjects (n = 21 AA, and n =
17 CA). However, as noted in Methods, power estimates
based on the present and prior data from our laboratory
reveal that with about 20 subjects in each of two groups,
our method has an approximately 100% power of
detecting single gene expression differences if they are
1.5-fold or greater, with erosion of power for lower fold
changes. In practice, as is evident here, we have found
that the potential sensitivity of the method has some-
what greater power than predicted.
Verification
Although we cannot “increase the n” for the present
study (since an aspect of the method is use of a single
lot of chips and a single batch of culture components),
we did seek verification of our present results by exam-
ining another data set.
We applied the present GSEA analysis method to a
previous (and non-overlapping) group of AA (n = 18)
versus CA (n = 9) that were controls for our previous
sickle stroke study [37], and we again identified a signi-
ficant difference for shear stress responsiveness genes:
P = .033, FDR = .140. However, this significance was
weaker than the current one because it was true only for
the core enrichment sub-group of the shear responsive-
ness gene set (that is, the sub-group that actually accounts
for the present implication of that biological system
(Table 3)). This probably is because the prior subject
groups were of less homogeneous age range (18 to 60),
and group size was much smaller. Furthermore, subjects
for that previous study were recruited from our health
center itself, so either or both CA and AA groups could
have been enriched for those with established disease (that
is, potentially having higher genetic risk profile).
Adding additional support to the present results, we
note that for those single genes that exhibited significant
differential expression for both previous and current AA
versus CA data sets, the correlation between them for the
fold-change (AA versus CA) was excellent (r = .810).
Finally, we now understand that our preliminary observa-
tion in that prior report that shear stress responsiveness
did not differ for comparison of AA versus CA [37], was
simply because it employed a much less-sensitive (and
now discarded) method for analysis. Verifying this, appli-
cation of that old method to the present study groups also
fails to identify the significant AA versus CA differences
evident for the present study groups. In aggregate, these
considerations provide verification for the present results.
Conclusions
Using blood outgrowth endothelial cells (BOEC) as
reporter cells, we determined whether, at the level of
gene expression, there might be insights related to the
Wei et al. BMC Medicine 2011, 9:2
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At the high stringency threshold requiring FDR = 0, this
approach successfully identified 31 genes that exhibited
differential expression among AA. At the more custom-
ary stringency level requiring FDR <.05 considerably
more were differentially expressed (221 transcripts
representing 204 genes). Many of the identified genes
are directly relevant to endothelial cell biology, for
example to vasoregulation or angiogenesis. In our sepa-
rate approach, use of pre-determined gene sets to survey
expression within each of nine biological systems rele-
vant to endothelial cell biology revealed an apparent
tonic increase for many genes within the biology of
shear stress responsiveness, which is a major determi-
nant of endothelial phenotype and vascular homeostasis,
including its regulation of vascular tone. Consequently,
our results provide support for the concept that inher-
ited inter-individual variation in endothelial gene expres-
sion, reflecting continent-of-origin, might impact on
endothelial cell and vascular biology and, thereby, upon
disparity in vascular and cancer disease burdens for AA
compared to CA. Also, our results identify needed
research directions.
It is true that the present approach requires participa-
tion of subjects that are of known genotype or clinical
phenotype (in terms relevant to the specific study question
at hand), as well as very meticulous performance of
laboratory procedures. Nonetheless, the ability of this
method to provide information from small groups of sub-
jects suggests that it may be of substantial value to future
studies of genotype-phenotype correlation as the field of
functional genomics evolves toward a whole cell, systems
biology perspective.
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